SCHILLING REDLICH, ANDREA INGRID
Thumbnail Image
Preferred name
SCHILLING REDLICH, ANDREA INGRID
Main Affiliation
Email
aschilling@udd.cl
ORCID
Scopus Author ID
7101797606

Research Output

2023 2023 2022 2022 2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 2014 2014 0.0 0.0 0.5 0.5 1.0 1.0 1.5 1.5 2.0 2.0 2.5 2.5 3.0 3.0

Filters

1
15
15
Reset filters

Settings
Now showing 1 - 10 of 15
No Thumbnail Available
Publication

Beneficios no anticonceptivos de 0,02 mg de etinilestradiol/2 mg de acetato de clormadinona administrados en un régimen de 24+4 días

2011 , Hans Peter Zahradnik , Aida Hanjalic-Beck , SCHILLING REDLICH, ANDREA INGRID

View
No Thumbnail Available
Publication

Disparities in Stroke Incidence Over Time by Sex and Age in Latin America and the Caribbean Region 1997 to 2021: A Systematic Review and Meta‐Analysis

2023 , Marilaura Nuñez , Carlos Delfino , Claudia Asenjo‐Lobos , SCHILLING REDLICH, ANDREA INGRID , LAVADOS GERMAIN, PABLO MANUEL , Craig S. Anderson , MUÑOZ VENTURELLI, PAULA ANDREA

Background High‐income country studies show unfavorable trends in stroke incidence (SI) in younger populations. We aimed to estimate temporal change in SI disaggregated by age and sex in Latin America and the Caribbean region. Methods and Results A search strategy was used in MEDLINE, WOS, and LILACS databases from 1997 to 2021, including prospective population‐based observational studies with first‐ever stroke incidence in Latin America. Reports without data broken down by age and sex were excluded. Risk of bias was assessed with The Joanna Briggs Institute's guide. The main outcomes were incidence rate ratio and relative temporal trend ratio of SI, comparing time periods before 2010 with after 2010. Pooled relative temporal trend ratios considering only studies with 2 periods in the same population were calculated by random‐effects meta‐analysis. Meta‐regression analysis was used to evaluate incidence rate determinants. From 9242 records identified, 6 studies were selected including 4483 first‐ever stroke in 4 101 084 individuals. Crude incidence rate ratio in younger subjects (<55 years) comparing before 2010:after 2010 periods showed an increase in SI in the past decade (incidence rate ratio, 1.37 [95% CI, 1.23–1.50]), in contrast to a decrease in older people during the same period (incidence rate ratio, 0.83 [95% CI, 0.76–0.89]). Overall relative temporal trend ratio (<55:≥55 years) was 1.65 (95 CI%, 1.50–1.80), with higher increase in young women (pooled relative temporal trend ratio, 3.08 [95% CI, 1.18–4.97]; P for heterogeneity <0.001). Conclusions An unfavorable change in SI in young people, especially in women, was detected in population‐based studies in the past decade in Latin America and the Caribbean. Further investigation of the explanatory variables is required to ameliorate stroke prevention and inform local decision‐makers. Registration URL: https://www.crd.york.ac.uk/prospero/ Identifier: CRD42022332563.

View
No Thumbnail Available
Publication

Criterios Médicos de elegibilidad para el uso de anticonceptivos de la OMS

2017 , Daniela Capella S , Andrea Schilling R , Claudio Villaroel Q

View
No Thumbnail Available
Publication

Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines

2015 , Andrea Schilling , Mercedes Macias Parra , Maricruz Gutierrez , Jaime Restrepo , Santiago Ucros , Teobaldo Herrera , Eli Engel , Luis Huicho , Marcia Shew , Roger Maansson , Nicole Caldwell , Alain Luxembourg , Ajoke Sobanjo ter Meulen

BACKGROUND: This study in 11- to 15-year-old boys and girls compared the immunogenicity and safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] vaccine) administered either concomitantly or nonconcomitantly with 2 vaccines routinely administered in this age group (Menactra [MCV4; Neisseria meningitidis serotypes A/C/Y/W-135] or Adacel [Tdap; diphtheria/tetanus/acellular pertussis]). METHODS: Participants received 9vHPV vaccine at day 1 and months 2 and 6; the concomitant group (n = 621) received MCV4/Tdap concomitantly with 9vHPV vaccine at day 1; the nonconcomitant group (n = 620) received MCV4/Tdap at month 1. Antibodies to HPV-, MCV4-, and Tdap-relevant antigens were determined. Injection-site and systemic adverse events (AEs) were monitored for 15 days after any vaccination; serious AEs were monitored throughout the study. RESULTS: The geometric mean titers for all HPV types in 9vHPV vaccine 4 weeks after dose 3, proportion of subjects with a fourfold rise or greater in titers for 4 N meningitidis serotypes 4 weeks after injection with MCV4, proportion of subjects with antibody titers to diphtheria and tetanus ≥0.1 IU/mL, and geometric mean titers for pertussis antigens 4 weeks after injection with Tdap were all noninferior in the concomitant group compared with the nonconcomitant group. Injection-site swelling occurred more frequently in the concomitant group. There were no vaccine-related serious AEs. CONCLUSIONS: Concomitant administration of 9vHPV vaccine with MCV4/Tdap was generally well tolerated and did not interfere with the antibody response to any of these vaccines. This strategy would minimize the number of visits required to deliver each vaccine individually.

View
No Thumbnail Available
Publication

Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile

2023 , Nicole Le Corre , Katia Abarca , Patricio Astudillo , Marcela Potin , Sofía López , Macarena Goldsack , Vania Valenzuela , SCHILLING REDLICH, ANDREA INGRID , Victoria Gaete , Lilian Rubio , Mario Calvo , Loreto Twele , Marcela González , Daniela Fuentes , Valentina Gutiérrez , Felipe Reyes , Lorena I. Tapia , Rodolfo Villena , Angello Retamal-Díaz , Antonio Cárdenas , Eduardo Alarcón-Bustamante , Xing Meng , Qianqian Xin , José V. González-Aramundiz , María Javiera Álvarez-Figueroa , Pablo A. González , Susan M. Bueno , Jorge A. Soto , Cecilia Perret , Alexis M. Kalergis

During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.

View
No Thumbnail Available
Publication

Adolescents find it easy to collect their own samples to study sexually transmitted infections

2017 , ANDREA HUNEEUS VERGARA , FERNANDEZ ARANCIBIA, MARIO , SCHILLING REDLICH, ANDREA INGRID , Paulina Parra , Aleksandra Zakharova

View
No Thumbnail Available
Publication

Prevalence and management of condylomas in consulting population in Chile: "DIACON study" [Prevalencia y manejo de condilomas en poblacion consultante en Chile: estudio "DIACON"]

2019 , Andrea Schilling R. , Andrea Huneeus V. , Alejandra Massoc P. , Francisca Rivera M. , Gabriel Cavada Ch. , SCHILLING REDLICH, ANDREA INGRID

View
No Thumbnail Available
Publication

Cervical Artery Dissection in Postpartum Women after Cesarean and Vaginal Delivery

2022 , Francisca Urrutia , MAZZON AGURTO, ENRICO , BRUNSER, ALEJANDRO , DIAZ TAPIA, VIOLETA DEL CARMEN , CALDERON GIADROSIC, JUAN FRANCISCO , STECHER GUZMAN, XIMENA PATRICIA , Tomas Bernstein , Paulo Zuñiga , SCHILLING REDLICH, ANDREA INGRID , MUÑOZ VENTURELLI, PAULA

View
No Thumbnail Available
Publication

Acceptability of HPV Vaccines: A Qualitative Systematic Review and Meta-Summary

2023 , María-Teresa Urrutia , Alejandra-Ximena Araya , Macarena Gajardo , Macarena Chepo , Romina Torres , SCHILLING REDLICH, ANDREA INGRID

In 2006, the human papillomavirus (HPV) vaccine was approved for use as an effective intervention for reducing the risk of developing cervical cancer; however, its successful implementation is dependent on acceptability. This study aims to provide a comprehensive understanding of the reasons that favor or do not favor the acceptability of HPV vaccines. Methods: We conducted a systematic review and meta-summary of qualitative research on 16 databases. A total of 32 articles that considered the perspectives of vaccine users, their parents, and the professionals who care for them were reviewed. Synthesis was conducted as described by Sandelowski and Barroso. Results: We used inductive and deductive methods to obtain a total of 22 dimensions, out of which three issues stood out that should be considered to improve acceptability and are formed by three groups of study, namely, information about the vaccine, fears and side effects, and sexuality associated with the vaccine. Conclusions: Acceptability, as well as adherence to HPV vaccination, is a complex concept. This review highlights the perspectives of the three sets of actors involved in the process (i.e., users, parents, and professionals) and views these factors in relation to acceptability as a guide for new interventions.

View
No Thumbnail Available
Publication

Prevalence of Chlamydia Trachomatis, Neisseria Gonorrhoeae, and Trichomonas Vaginalis Infection in Chilean Adolescents and Young Adults

2018 , Andrea Huneeus , SCHILLING REDLICH, ANDREA INGRID , FERNANDEZ ARANCIBIA, MARIO

View